Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutational status of KRAS, NRAS, and BRAF in primary clear cell ovarian carcinoma.

Virchows Archiv : an international journal of pathology - 1 Aug 2014

Zannoni Gian Franco, Improta Giuseppina, Chiarello Gaia, Pettinato Angela, Petrillo Marco, Scollo Paolo, Scambia Giovanni, Fraggetta Filippo

Abstract excerpt

Ovarian clear cell carcinoma (OCCC) is a subtype of epithelial ovarian cancer with characteristic biological features and aggressive clinical behavior. OCCCs show a pattern of gene mutations different from other type I ovarian malignancies, notably a higher frequency of PIK3CA mutations. In low grade serous ovarian cancer, KRAS and BRAF mutations are frequent, but little data are available on the mutational...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma, Clear Cell
Share to Codon

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to DNA, Neoplasm

Share to GTP Phosphohydrolases

Share to Ovarian Neoplasms

Share to Proto-Oncogene Proteins B-raf

Share to Proto-Oncogene Proteins p21(ras)

Share to ras Proteins

Source

Identifiers

PMID: 24889043
DOI: 10.1007/s00428-014-1599-1

Genes

KRAS
BRAF
NRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutational status of KRAS, NRAS, and BRAF in primary clear cell ovarian carcinoma.PMID 24889043Read ↗

Molecular status of PI3KCA, KRAS and BRAF in ovarian clear cell carcinoma: an analysis of 63 patients.Semantic proximity Read ↗

Molecular diagnosis in type I epithelial ovarian cancer.Semantic proximity Read ↗

High frequency of BRAF mutations and concomitant KRAS mutations in Taiwanese ovarian clear cell carcinoma.Semantic proximity Read ↗

Comprehensive genomic profiling (CGP) of ovarian clear cell carcinomas (OCCC) identifies clinically relevant genomic alterations (CRGA) and targeted therapy optionsSemantic proximity Read ↗

Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma.Semantic proximity Read ↗

Clinical analysis and literature review of a case of ovarian clear cell carcinoma with PIK3CA gene mutation: A case report.Semantic proximity Read ↗

PPP2R1A mutation is a rare event in ovarian carcinoma across histological subtypes.Semantic proximity Read ↗

Clinicopathological correlates and prognostic significance of KRAS mutation status in a pooled prospective cohort of epithelial ovarian cancer.Semantic proximity Read ↗

Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma.Semantic proximity Read ↗

p53 mutations and overexpression affect prognosis of ovarian endometrioid cancer but not clear cell cancer.Semantic proximity Read ↗

Mutational analysis of BRAF and KRAS in ovarian serous borderline (atypical proliferative) tumours and associated peritoneal implants.Semantic proximity Read ↗

CCNE1 copy-number gain and overexpression identify ovarian clear cell carcinoma with a poor prognosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.